Ayala Pharmaceuticals, Inc.
Ayala Pharmaceuticals, Inc. (ADXS) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
adxs · stock forecast · 8 analysts (3M) · FMP · updated Oct 3, 2025
Analyst Rating & Consensus
Based on 8 Wall Street analysts in the past 3 months
Buy
8 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $0.60
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-16 | $0.60 | ↑ 0.00% |
1-day model range: $0.59–$0.62. Peak: $0.62 (+0.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · ADXS · Jun 15, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-05-30 | Ladenburg Thalmann | Upgrade ↑ | Neutral→Buy |
| 2020-11-25 | Jefferies | Downgrade ↓ | Buy→Hold |
| 2020-11-25 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2020-11-25 | Barclays | Maintains | Overweight→Overweight |
| 2020-11-25 | H.C. Wainwright | Downgrade ↓ | Buy→Neutral |
| 2020-11-25 | H.C. Wainwright | Maintains | Buy→Buy |
| 2018-12-18 | H.C. Wainwright | Downgrade ↓ | Buy→Neutral |
| 2018-06-13 | Jefferies | Downgrade ↓ | Buy→Hold |
| 2018-03-14 | H.C. Wainwright | Maintains | Buy→Buy |
| 2018-03-13 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
Wall Street analysts have recently issued updated ratings on Ayala Pharmaceuticals, Inc. (ADXS) stock. Of the recent 18 rating actions, 1 were upgrades and 4 were downgrades. 8 analysts currently cover ADXS.
Analyst Recommendation Trends
ADXS analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
↓ 99.9% YoY
Revenue Next Year
$3M
↑ 99566.7% YoY
EPS This Year
$-48.00
EPS Next Year
$-16.00
↓ 66.7% YoY
EPS ForecastReported vs Estimated
Analysts forecast ADXS EPS of $-48.00 for the current fiscal year, based on estimates from 1 analysts. The ADXS revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The ADXS stock forecast is supported by two independent data sources: analyst consensus ratings from 8 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ADXS price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The ADXS short-term stock prediction for tomorrow is $0.60 (+0.00%).
Ayala Pharmaceuticals, Inc. trades on OTC under the ticker ADXS. The ADXS stock outlook for 2027 is broadly positive, supported by a Buy consensus among 75% of covering analysts.
Frequently asked questions
ADXS forecast · 8 questionsAccording to 8 Wall Street analysts, the average 12-month ADXS price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $0.60.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.